Abstract: The invention provides a colonic microbiota responsive polymer characterized in that it is prepared by the polymerization of a response monomer and a linking monomer, wherein the response monomer is a cellobiose with a B-(1,4)-glucoside bond or/and a lactose with a p-galactoside bond; the linking monomer is a monomer that reacts with the hydroxyl group of the response monomer to form an ester or ether directly or by a crosslinking agent. The invention also provides a method for preparation of a colonic microbiota responsive polymer, a degradable film based on the polymer and a preparation method thereof. By means of the characteristics that B-(1,4)-glucoside bond provided by cellobiose or/and p-galactoside bond provided by lactose monomer unit in the polymer can specifically respond to the high abundance of microbiotas (p-glucosidase or/and p-galactosidase) in the colon to specifically degrade in the colon, a colon-targeted delivery system for diagnosis and treatment of colon diseases is constructed.

Abstract: A preparation method of drug-loaded micelles of an absorbable vascular stent coating for angiostenosis in an infant is provided, including the following steps: S1: dissolving a drug to be encapsulated in an appropriate amount of an emulsifying agent, adding a chitosan-poly(p-dioxohone) amphiphilic block copolymer (chitosan-b-PPDO copolymer), and thoroughly mixing to obtain a drug-copolymer solution; S2: adding the drug-copolymer solution obtained in S1 dropwise to an emulsifying agent aqueous solution prepared in advance, and continuously stirring to obtain a stable drug-loaded micellar solution; and S3: removing the emulsifying agent from the micellar solution obtained in S2 through vacuum evaporation, stirring a resulting concentrate, and centrifuging the concentrate to obtain a supernatant; and filtering the supernatant to obtain a filtrate, and subjecting the filtrate to dialysis to obtain the drug-loaded micelles.

Abstract: A use of an intervertebral disc fibrosis-inducing substance in preparation of medication, where the medication is used for the treatment of degenerative spinal diseases. The inventors of the present disclosure make use of the pro-fibrotic effect of the intervertebral disc fibrosis-inducing substance and the auxiliary effect of the fibroblast to achieve further treatment of intervertebral disc degeneration. The simultaneous administration of the above two drugs can reasonably control the degeneration and achieve the purpose of stepped treatment, thereby having clinical transformation value. In addition, the therapy combining the intervertebral disc fibrosis-inducing substance with the cell in the present disclosure allows the treatment regimen more personalized.

Abstract: A use of nitrogen-doped carbon fluorescent quantum dots in preparation of aerobic glycolysis detection products is provided. The carbon-nitrogen fluorescent quantum dots are selected from one or more of C3N4 quantum dots, C2N quantum dots, and C3N quantum dots. The aerobic glycolysis detection products are reagents, based on a final volume of the reagents, the reagents comprise the carbon-nitrogen fluorescent quantum dots with a final concentration of 1 ?g/mL-1 mg/mL. The present disclosure realizes fluorescent labeling of NAD+ in living cells using the carbon-nitrogen fluorescent quantum dots, thus achieving fluorescent labeling and imaging of cells having aerobic glycolysis, which has the advantages of low cost, high efficiency, rapidity, and high accuracy.

Abstract: Methods of preparing and using a highly active blood coagulation factor XI mutant and a gene therapy/editing vector thereof and a recombinant/fusion protein thereof. The nucleotide sequence of the mutant is as shown in SEQ ID NOs: 1-6, and the amino acid sequence is as shown in SEQ ID NO: 7.

Abstract: A preparation method of drug-loaded micelles of an absorbable vascular stent coating for angiostenosis in an infant is provided, including the following steps: Si: dissolving a drug to be encapsulated in an appropriate amount of an emulsifying agent, adding a chitosan-poly(p-dioxohone) amphiphilic block copolymer (chitosan-b-PPDO copolymer), and thoroughly mixing to obtain a drug-copolymer solution; S2: adding the drug-copolymer solution obtained in S1 dropwise to an emulsifying agent aqueous solution prepared in advance, and continuously stirring to obtain a stable drug-loaded micellar solution; and S3: removing the emulsifying agent from the micellar solution obtained in S2 through vacuum evaporation, stirring a resulting concentrate, and centrifuging the concentrate to obtain a supernatant; and filtering the supernatant to obtain a filtrate, and subjecting the filtrate to dialysis to obtain the drug-loaded micelles.

Abstract: A muscle function preservation type total temporomandibular joint prosthesis includes an articular fossa member (1) and an articular head member (2) abutting against the articular fossa member (1). The articular head member (2) includes a mandibular trailing edge fixing plate (21), a sigmoid notch fixing plate (22) and an articular head portion (23). The mandibular trailing edge fixing plate (21) is connected to a bottom end of the articular head portion (23) and extends downwards, and has a plate-shaped structure and includes a mandibular-trailing-edge-surface attaching surface. The sigmoid notch fixing plate (22) protrudes from one side of the mandibular trailing edge fixing plate (21) and extends in a direction away from the mandibular trailing edge fixing plate (21), and has a plate-shaped structure and includes a mandibular-ramus-proximal-sigmoid-notch-portion attaching surface.

Abstract: The present invention relates to the field of hemodialysis and peritoneal dialysis, in particular to a fat emulsion dialysate, and preparation method and the use thereof. Provided in the present invention is a fat emulsion dialysate, comprising a long-chain fat emulsion oil, a medium-chain triglyceride, an anti-oxidant, sodium oleate, glycerin, phospholipid, and a solvent. Compared with traditional dialysis, the fat emulsion dialysate provided by the present invention has a better advantage for protein-bound toxin removal. In addition, the fat emulsion dialysate not only has a simple preparation method and a low cost, but also has good stability and safety, and remains stable at room temperature for 14 days without obvious precipitation. Thus, the fat emulsion dialysate can become a hemodialysis dialysate or peritoneal dialysate with broad application prospects, and has good industrialization prospects.

Abstract: A high-activity blood coagulation factor XI mutant Ala570Thr (A570T), having nucleotide sequences as shown in SEQ ID NOs: 1-4 and an amino acid sequence as shown in SEQ ID NO: 5, is provided. The mutant is resistant to a physiological inhibitor thereof after being activated from a zymogen state to an active enzyme. Therefore, the mutant has a very high blood coagulation activity and a stronger catalytic ability for a non-physiological substrate; and the mutant is applied to the treatment of hemorrhagic diseases, and has good prospects in terms of gene therapy, gene editing and recombinant protein replacement treatments.

Abstract: An intelligent mouth opening rehabilitation device is provided, including: a body, an end of the body is provided with an upper bite pad and a lower bite pad; a pressure sensor, for detecting pressure data on the upper bite pad and/or the lower bite pad; a stepping motor, for driving the upper bite pad and/or the lower bite pad to swing longitudinally; and a processor, for controlling the stepping motor to operate or stop according to the pressure data and/or a preset training instruction, thereby driving the upper bite pad and/or the lower bite pad to swing longitudinally or to stop. Compared with traditional mouth opening rehabilitation devices, the intelligent mouth opening rehabilitation device controls automatically the upper bite pad and/or the lower bite pad to swing longitudinally, so that a mouth opening training is more accurate, and more controllable. Therefore, a rehabilitation effect is greatly improved.

Abstract: An injectable in situ pore-forming hydrogel system and its preparation method and use are provided. The injectable in situ pore-forming hydrogel system uses an injectable hydrogel as a continuous base phase, and isolated live cells and magnesium particles are distributed in the continuous base phase, where the injectable hydrogel is a precursor or prepolymer of hydrogel, which can form hydrogel by cross-linking. The injectable in situ pore-forming hydrogel system can be used to create pores while the gel encapsulates live cells, which makes use of both the injectability and porous structures of hydrogel, which is important for the repair of cavitary, surgically difficult and irregularly defective tissues; meanwhile, magnesium particles generate magnesium ions after the former undergoes gas production and degradation, which can improve the bioactivity of the gel and aid in tissue repair.

Abstract: An oral colon-targeted delivery system is described, which includes a bacterial flora sensitive layer which contains polysaccharides and covers the exterior of active ingredients, a pH sensitive layer which contains any polymer composition dissolved under the condition of pH?7 and covers the exterior of the bacterial flora sensitive layer. A preparation method and applications of the delivery system are also described. According to the oral colon-targeted delivery system combined with the pH sensitive and bacterial flora sensitive mechanisms, the selective dissolution and release of active ingredients in the colon site are effectively improved by using double-layer protection so that the therapeutic or diagnostic effect is enhanced, and the application prospect is broad.

Abstract: The present disclosure provides methods and kits for diagnosing and assessing SAGE1-positive disorders, and compositions and methods for treating SAGE1-positive disorders. The present disclosure further provides SAGE1 complexes and methods and composition for inhibiting SAGE1 complexes and treating SAGE1-positive disorders.

Abstract: The present application provides an automatic knife stop device and a system for fibula cutting, a computer equipment, and a medium. The device includes: an acquisition module; a threshold module; and a judgment module. The present application can avoid the destruction of blood vessels during shaping and greatly improve the success rate of surgery, while greatly improve the robustness of the control system by increasing the strength of the force feedback signal.

Abstract: The present application provides an automatic knife stop device and a system for fibula cutting, a computer equipment, and a medium. The device includes: an acquisition module; a threshold module; and a judgment module. The present application can avoid the destruction of blood vessels during shaping and greatly improve the success rate of surgery, while greatly improve the robustness of the control system by increasing the strength of the force feedback signal.

Abstract: Use of glycerol in preparing an adipose tissue cryopreservation protective agent and the adipose tissue cryopreservation protective agent. Based on the total volume of the adipose tissue cryopreservation protective agent, the adipose tissue cryopreservation protective agent includes: glycerol with a volume fraction of 60-80%; 0.090-0.200 g/ml trehalose; and a PBS buffer serving as the solvent. The adipose tissue cryopreservation protective agent is free of DMSO and other protective agents having biological toxicity, poses no toxicity to cells and tissues, and causes no safety problem during clinical use even in a case of incomplete elution. The adipose tissue cryopreservation protective agent is free of xenoantigen and has low cost. With glycerol and trehalose being clinically approved medicinal ingredients and inexpensive products, the agent of the present disclosure contains no costly products such as human albumin, thus providing increased possibility for clinical use and promotion.

Abstract: The present disclosure provides the use of a recombinant human secretory DDRGK1. Experiments demonstrate that the recombinant human secretory DDRGK1 prepared by the present disclosure can be used in the preparation of biological medicines for treating intervertebral disc degeneration, fractures or bone defects. The recombinant human secretory DDRGK1 of the present disclosure provides a promising direction for the treatment of bone related diseases and has obtained firm scientific evidence, thereby expanding the further application of recombinant human secretory DDRGK1 in clinical practice.

Abstract: An injectable in situ pore-forming hydrogel system and its preparation method and use are provided. The injectable in situ pore-forming hydrogel system uses an injectable hydrogel as a continuous base phase, and isolated live cells and magnesium particles are distributed in the continuous base phase, where the injectable hydrogel is a precursor or prepolymer of hydrogel, which can form hydrogel by cross-linking. The injectable in situ pore-forming hydrogel system can be used to create pores while the gel encapsulates live cells, which makes use of both the injectability and porous structures of hydrogel, which is important for the repair of cavitary, surgically difficult and irregularly defective tissues; meanwhile, magnesium particles generate magnesium ions after the former undergoes gas production and degradation, which can improve the bioactivity of the gel and aid in tissue repair.

Abstract: The present disclosure relates to the field of medicines, in particular to the use of IGSF10 in the preparation of a bone tissue regeneration product, especially the use of IGSF10 in combination with BMP in the preparation of a product for promoting bone tissue regeneration. The product includes a periodontal bone defect repair product, a jaw bone defect repair product and/or a skull defect repair product. The new use of IGSF10 of the present disclosure can reduce the effective concentration of BMP without obvious adverse reactions, thereby exploring a method to promote bone tissue regeneration and providing new ideas for the treatment of bone defects.

Abstract: The present invention relates to the field of medical devices, and relates to an electrophysiological test method for an auditory brainstem implant (ABI) and a recording electrode used therein. According to the method of the present invention, there is no need to subcutaneously place an additional recording electrode for a patient, which simplifies preoperative preparation. Moreover, the method has advantages of a high signal-to-noise ratio, a fast response speed, a short recording time, and a large anti-interference ability, thus can effectively improve efficiency of intraoperative electrode test. The method is suitable for use in an auditory brainstem implantation surgery. Besides, the present invention enables the auditory brainstem implantation to be located more accurately, thereby expanding a scope of application.